Penumbra, Inc. (PEN) Stock: Price, Forecast & Analyst Target
Penumbra, Inc. (PEN) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $320.00 (-0.19%), as of the Nov 19, 2026 trading session; market cap $12.6B. Expected results Feb 24, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 18.71× (cash as of Sep 30, 2026) · expected results Feb 24, 2027
Penumbra, Inc. · PEN · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Penumbra sells clot-removal, embolization and access devices for neurovascular and peripheral vascular procedures, with demand tied to clinician adoption and procedure use rather than broad healthcare spending. Revenue continues to expand, but recent earnings have not kept pace with sales. The case depends on whether Penumbra can convert further adoption of its thrombectomy platforms into stronger operating profit and cash generation without commercial spending absorbing the gains.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Penumbra (PEN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $355M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 19.12 · Piotroski F 5
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $320.00 | |
| Change on the day | -0.19% | |
| 52-week range | $276.01–$362.41 | |
| Market capitalisation | $12.6B | — |
| Price / earnings (trailing) | 79.98 | |
| Shares traded on the day | 195.8K | |
| Beta (volatility vs the S&P 500) | 0.69 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Penumbra (PEN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Penumbra (PEN), and what does it report?
Short answer · as of
Penumbra designs, manufactures and markets systems used to remove thrombus, treat aneurysms and occlude peripheral vessels.
Research dated 2026-09-13.
Its portfolio spans computer-assisted vacuum thrombectomy, aspiration systems, catheters, coils, delivery devices and neurosurgical tools, sold through direct sales organizations and distributors.
This is not a diversified medical-supplies business. The reported revenue reflects demand for focused neurovascular and peripheral vascular products such as the Penumbra System, Indigo System, Lightning Flash and Ruby Embolization Platform. Historical segment reporting places peripheral vascular alongside neuro as the principal reporting shape.
What do the latest results show for Penumbra (PEN)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $355M.
Research dated 2026-09-13.
Revenue advanced from the preceding period and gross profit rose with it. Operating profit and net income also improved sequentially, yet both remained below their recent peak, while selling and administrative expense continued to climb.
The latest revenue result was close to expectations, but earnings fell short; the preceding report showed the same split between resilient sales and weaker earnings delivery. The statements point to expense conversion, not a collapse in product demand, as the immediate pressure: commercial spending has expanded faster than revenue over the comparable period, leaving operating profit only slightly higher.
The broader annual record remains constructive. Revenue has grown across the presented years, profitability recovered sharply in the latest completed year, and operating cash flow has stayed positive. Management commentary is not needed to establish the tension: sales momentum remains visible, while recent earnings and cash conversion have softened from stronger periods.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $410.14M Sep 30, 2026
- Latest quarter · R&D
- $25.36M Sep 30, 2026
- Latest quarter · SG&A
- $204.20M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $50.74M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $410.14M | $25.36M | $204.20M | $50.74M |
| Jun 30, 2026 | $390.05M | $25.40M | $198.51M | $41.04M |
| Mar 31, 2026 | $374.76M | $22.38M | $192.79M | $38.23M |
| Dec 31, 2025 | $385.38M | $21.79M | $181.10M | $59.23M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $410.14M Oct 29, 2026
- Latest report · revenue estimate
- $401.41M Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Below estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $410.14M | $401.41M | $1.0700 | $1.2000 |
| Jul 30, 2026 | $390.05M | $389.64M | $0.8800 | $1.1600 |
| May 6, 2026 | $374.76M | $370.47M | $0.8200 | $1.0400 |
| Feb 25, 2026 | $385.38M | $361.87M | $1.1800 | $1.1100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $355M | $46M | $1.17 (diluted) |
| Q4 FY2025 | $385M | $47M | $1.20 (diluted) |
| Q1 FY2026 | $375M | $33M | $0.82 (diluted) |
| Q2 FY2026 | $390M | $35M | $0.88 (diluted) |
What are the financial strengths and risks for Penumbra (PEN)?
Short answer · as of
Cash and short-term investments were $673.61M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $41.51M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Penumbra carries substantial net cash, with cash and short-term investments comfortably exceeding total debt and total liabilities. Liquidity has also accumulated steadily across the reported history, while the distress screen does not signal balance-sheet strain.
Operating cash flow has remained positive after capital spending, giving the business internal funding capacity for product development and commercial expansion. The latest cash-flow result weakened from the preceding period, however, so continued balance growth should not be mistaken for uniformly improving conversion.
The sharper risk sits in the income statement. Selling and administrative costs have risen quickly while recent earnings have lagged revenue expectations, and the valuation embeds high sales and earnings multiples despite modest earnings and free-cash-flow yields. Slower adoption or continued expense growth could therefore pressure both profit conversion and the market’s growth assumptions.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 79.98 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $41.51M Sep 30, 2026
- Previous quarter · operating cash flow
- $46.08M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $41.51M | −$15.11M |
| Jun 30, 2026 | $46.08M | −$13.54M |
| Mar 31, 2026 | $86.97M | −$13.67M |
| Dec 31, 2025 | $86.48M | −$18.43M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Penumbra (PEN)?
Short answer · as of
The next earnings report is expected on Feb 24, 2027.
Research dated 2026-09-13.
Penumbra’s next checkpoint is the relationship between product demand and expense conversion. Watch whether revenue keeps advancing, whether gross profit translates into faster operating-profit growth, and whether selling and administrative expense begins growing more slowly than sales.
Cash conversion deserves equal attention. A rebound in operating cash flow alongside continued cash accumulation would reinforce the quality of reported earnings; another decline while revenue rises would deepen the gap between commercial momentum and financial leverage.
Market estimates assume continued revenue and earnings expansion. The useful observation is not whether Penumbra clears a published estimate in isolation, but whether the recent pattern of near-plan sales and below-plan earnings begins to reverse.
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 5, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Penumbra compare with its peers?
Short answer
Penumbra's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Penumbra is a focused thrombectomy and embolization company rather than a broad device conglomerate. Its portfolio connects neurovascular and peripheral vascular intervention through aspiration systems, catheters, coils and access products, making adoption of a relatively concentrated product family more consequential to overall performance.
That focus offers direct exposure to procedure use and product adoption, but it also concentrates execution risk in vascular intervention and the commercial organization supporting it. The market values Penumbra as a growth business, so comparison with similar device makers should emphasize sales-to-profit conversion and cash generation, not revenue growth alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| Penumbra (PEN) — this page | $320.00 | $12.6B | 92 |
| $94.54 Nov 18, 2026 | $5.21B | 88 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| $370.17 Nov 18, 2026 | $9.95B | 77 5-pillar Nov 18, 2026 | |
| $156.24 Nov 19, 2026 | $9.83B | 76 5-pillar Nov 18, 2026 | |
| $85.69 Nov 18, 2026 | $9.47B | 73 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $320.00 – $320.00
- Consensus target
- $320.00
- Median target
- $320.00
Consensus record · Captured .
Measured against a quoted price of $320.00 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026
- Transactions
- 9
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 88.9% Period end Sep 30, 2026
- Previous quarter · ownership
- 87.8% Prior to period end Sep 30, 2026
- Reporting holders
- 456 Period end Sep 30, 2026
- Previous quarter · holders
- 477 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 4,300,206 |
| Hbk Investments L P | 1,881,725 |
| Vanguard Capital Management LLC | 1,704,378 |
| Vanguard Portfolio Management LLC | 1,634,275 |
| Ubs Group AG | 1,466,748 |
Tracked investors
Which of the 16 named investors we follow held PEN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PEN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Penumbra (PEN) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does the Indigo System contribute to Penumbra’s business?
The Indigo System extends Penumbra’s clot-removal portfolio into peripheral vascular procedures through aspiration-based thrombectomy. It makes peripheral intervention a core source of demand alongside the company’s neurovascular products.
Why can Penumbra’s revenue rise while earnings disappoint?
Recent reports paired resilient revenue with earnings below expectations. Selling and administrative expense has grown quickly, so additional gross profit has not flowed through proportionately to operating and net income.
What does the Ruby Embolization Platform add beyond Penumbra’s thrombectomy products?
Ruby consists of detachable coils for peripheral embolization, supported by delivery and packing products. It gives Penumbra exposure to vessel occlusion procedures as well as clot removal.
Can Penumbra fund further development of Lightning Flash and the Indigo System?
Cash and short-term investments exceed debt by a wide margin, and operating cash flow remains positive after capital spending. That provides internal funding capacity, although the recent decline in operating cash flow makes conversion an important continuing check.
What is the PEN stock price today?
The last price recorded for Penumbra, Inc. (PEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PEN price target?
The analyst consensus price target for Penumbra, Inc. (PEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 73 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com